Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 46 recruiting now early-phase tilt #130 of 28,707 conditions

Mantle Cell Lymphoma: early-phase trial registry

46 of 103 indexed Mantle Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #130 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

103 US clinical trials · 46 currently recruiting · #130 of 28,707 conditions by registered trial count

Mantle Cell Lymphoma: 103 US clinical trials tracked, 46 recruiting.

Mantle Cell Lymphoma is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 46 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.

Enrollment posture brief

Registry condition mantle-cell-lymphoma

OPEN 46 | RECR 45% | LATE 7 | EARLY 86 | RANK #130 | SPON 12

Volume-matched condition peers

Nearest open-share peer: Food Insecurity (45% recruiting · 38 trials)

Amyotrophic Lateral Sclerosi45.6%Mantle Cell Lymphoma (this)45%Chronic Kidney Disease31.1%Attention Deficit Hyperactiv28.2%Metabolic Syndrome26.9%
Open-enrollment share among volume-matched conditions near Mantle Cell Lymphoma

Mantle Cell Lymphoma lists 46 open slots (45% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mantle Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mantle Cell Lymphoma is recruiting above its size-band peers.

    46 of 103 indexed trials (44.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Mantle Cell Lymphoma trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 12 of 103 trials (11.7%). 71 distinct sponsors appear on at least one study for this condition label.

  3. Most Mantle Cell Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 43 among the 103 trials that report a genuine target (sentinel values excluded). 73 of those (70.9%) plan for fewer than 100 participants.

  4. Mantle Cell Lymphoma research is mostly interventional.

    96 interventional and 7 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 146Phase 240Phase 37

Open and recent trials

103 total, page 2 of 3

ACTIVE NOT RECRUITING Phase 1 190 participants

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

NCT03162536
ACTIVE NOT RECRUITING Phase 1 150 participants

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Nkarta

NCT05020678
ACTIVE NOT RECRUITING Phase 2 131 participants

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT02427620
ACTIVE NOT RECRUITING Phase 1 125 participants

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

BeiGene

NCT05471843
ACTIVE NOT RECRUITING Phase 2 120 participants

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Cellectar Biosciences

NCT02952508
ACTIVE NOT RECRUITING Phase 2 113 participants

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT01880567
ACTIVE NOT RECRUITING Phase 2 53 participants

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT04765111
ACTIVE NOT RECRUITING Phase 2 51 participants

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT03710772
ACTIVE NOT RECRUITING Phase 1 43 participants

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

University of Michigan Rogel Cancer Center

NCT03842696
ACTIVE NOT RECRUITING Phase 2 39 participants

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

Alliance Foundation Trials

NCT03478514
ACTIVE NOT RECRUITING Phase 2 37 participants

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Weill Medical College of Cornell University

NCT03863184
ACTIVE NOT RECRUITING Phase 1 36 participants

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Synthekine

NCT05665062
ACTIVE NOT RECRUITING Phase 2 33 participants

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

NCT02339922
ACTIVE NOT RECRUITING Phase 1 30 participants

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Bio-Path Holdings

NCT04072458
ACTIVE NOT RECRUITING Phase 1 27 participants

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Hackensack Meridian Health

NCT02446236
ACTIVE NOT RECRUITING Phase 2 23 participants

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Emory University

NCT03872180
ACTIVE NOT RECRUITING Phase 2 23 participants

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Dana-Farber Cancer Institute

NCT01661881
ACTIVE NOT RECRUITING Phase 1 23 participants

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Joshua Brody

NCT03153202
ACTIVE NOT RECRUITING Early Phase 1 22 participants

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT05495464
ACTIVE NOT RECRUITING Phase 2 22 participants

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

NCT03674411
ACTIVE NOT RECRUITING Phase 2 20 participants

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT03282396
ACTIVE NOT RECRUITING Phase 1 16 participants

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

M.D. Anderson Cancer Center

NCT03622788
ACTIVE NOT RECRUITING Phase 2 12 participants

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

NCT04783415
ACTIVE NOT RECRUITING Phase 2 9 participants

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

M.D. Anderson Cancer Center

NCT04189757
COMPLETED Phase 3 523 participants

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Janssen Research & Development

NCT01776840
COMPLETED Phase 3 447 participants

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Teva Branded Pharmaceutical Products R&D

NCT00877006
COMPLETED 174 participants

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Children's Oncology Group

NCT01000753
COMPLETED Phase 2 152 participants

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Millennium Pharmaceuticals

NCT00063713
COMPLETED Phase 2 151 participants

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Alliance for Clinical Trials in Oncology

NCT00310037
COMPLETED Phase 1 91 participants

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT03833180
COMPLETED Phase 1 66 participants

Ublituximab + Ibrutinib in Select B-cell Malignancies

TG Therapeutics

NCT02013128
COMPLETED Phase 1 60 participants

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

NCT00880815
COMPLETED Phase 3 54 participants

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Cephalon

NCT01073163
COMPLETED Phase 2 53 participants

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

National Cancer Institute (NCI)

NCT00114738
COMPLETED Phase 1 50 participants

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Massachusetts General Hospital

NCT00644189
COMPLETED Phase 2 50 participants

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Ascenta Therapeutics

NCT00275431
COMPLETED Phase 1 45 participants

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Dana-Farber Cancer Institute

NCT02268851
COMPLETED NA 45 participants

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

Pack Health

NCT05064787
COMPLETED Phase 1 42 participants

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

University of Nebraska

NCT00571493
COMPLETED Phase 1 39 participants

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Masonic Cancer Center, University of Minnesota

NCT03019666
COMPLETED Phase 2 36 participants

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

NCT00186628
COMPLETED Phase 2 29 participants

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

H. Lee Moffitt Cancer Center and Research Institute

NCT00609869
COMPLETED Phase 2 26 participants

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

National Cancer Institute (NCI)

NCT00005780
COMPLETED Phase 2 25 participants

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

University of Miami

NCT00878254
COMPLETED Phase 1 22 participants

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Acrotech Biopharma

NCT01851551
COMPLETED Phase 2 22 participants

Imexon for Relapsed Follicular and Aggressive Lymphomas

University of Rochester

NCT01314014
COMPLETED Phase 1 18 participants

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Calibr, a division of Scripps Research

NCT04450069
COMPLETED Phase 2 13 participants

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Washington University School of Medicine

NCT03623373
COMPLETED Phase 1 11 participants

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Cancer Institute (NCI)

NCT04599634
COMPLETED NA 10 participants

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Massachusetts General Hospital

NCT06004167
← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 46
Phase 2 40
Phase 3 7

Top Sponsors

M.D. Anderson Cancer Center 12 trials
City of Hope Medical Center 6 trials
Emory University 3 trials
National Cancer Institute (NCI) 3 trials
ECOG-ACRIN Cancer Research Group 2 trials
Alliance for Clinical Trials in Oncology 2 trials
Janssen Research & Development 2 trials
Dana-Farber Cancer Institute 2 trials
OHSU Knight Cancer Institute 2 trials
Masonic Cancer Center, University of Minnesota 2 trials

Named interventions

Most-linked intervention names on Mantle Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rituximab Drug
15 trials
Cyclophosphamide Drug
12 trials
Acalabrutinib Drug
11 trials
Bendamustine Drug
10 trials
Ibrutinib Drug
10 trials
Cytarabine Drug
8 trials
Rituximab Biological
7 trials
Bone Marrow Biopsy Procedure
7 trials

US sites by state

Facility locations filed on Mantle Cell Lymphoma trials. A trial with sites in several states counts in each.

California 38 trials
Texas 25 trials
New York 20 trials
Massachusetts 18 trials
Colorado 14 trials
North Carolina 13 trials
Maryland 13 trials
Illinois 13 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mantle Cell Lymphoma page

103 registered trials, 46 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mantle Cell Lymphoma condition card totals 103 registered trials; most-linked intervention Rituximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.